Hugh McMillan

hugh-mcmillan

Investigator

Professor, Pediatric Neurology, University of Ottawa

Pediatric Neurologist and Neuromuscular specialist at the Children’s Hospital of Eastern Ontario


NMD4C Involvement: Pillar 2: Clinical Research

Email Hugh

Biography

Dr. McMillan is a Pediatric Neurologist with specialization in Clinical Neurophysiology and Neuromuscular medicine at the Children’s Hospital of Eastern Ontario. He is a Professor in the Department of Pediatrics, Faculty of Medicine at the University of Ottawa.  He holds a Clinical Research Chair (Level 2) at the University of Ottawa and is a Clinical Investigator at the CHEO Research Institute

He has been an author of over 125 publications in peer-review journals and was a co-editor of a Pediatric Electromyography textbook.  He is also a leader in clinical and translational research in pediatric neurology & neuromuscular medicine.

Dr. McMillan completed a Neuromuscular and Neurophysiology Fellowship at Boston Children’s Hospital, Harvard University and the Lahey Clinic, Tufts University; a Pediatric Neurology Residency at the Children’s Hospital of Eastern Ontario, University of Ottawa and a Pediatric Residency at McMaster Children’s Hospital, McMaster University.


Recent Publications

Dang, UJ, Damsker, JM, Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC et al.. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024.102 (5)e208112 PMID:38335499

Muntoni, F, Byrne, BJ, McMillan, HJ, Ryan, MM, Wong, BL, Dukart, J et al.. The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy. Neurol Ther. 2024.13 (1)183-219 PMID:38190001

Longmuir, PE, Chubbs Payne, A, Beshara, N, Brandão, LR, Wright, FV, Pohl, D et al.. Quick, Effective Screening Tasks Identify Children With Medical Conditions or Disabilities Needing Physical Literacy Support. Pediatr Exerc Sci. 2024. 1-11 PMID:38171358

McMillan, HJ, Lochmüller, H. Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophy. Muscle Nerve. 2024.69 (1)4-6 PMID:37969074

Saettini, F, Guerra, F, Fazio, G, Bugarin, C, McMillan, HJ, Ohtake, A et al.. Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations. J Clin Immunol. 2023.43 (8)2126 PMID:37921915

See more on PubMed